Balaji Amines Limited received a Warning cum Advisory Letter from the Securities and Exchange Board of India (SEBI) dated September 29, 2026. The regulator cited the company’s failure to disclose material events, specifically a DGFT order and an FDA warning, within the mandated 24-hour window.

The disclosure was submitted to BSE and NSE on October 1, 2026, pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015. SEBI observed that the company did not report the DGFT’s placement of its license on the Denied Entity List or a strict warning from the Maharashtra Food and Drug Administration (FDA) in a timely manner.

Regulatory Non-Compliance Details

SEBI noted that the Directorate General of Foreign Trade (DGFT) placed the company on the Denied Entity List via an order dated August 13, 2024. This action stemmed from a violation of export obligations under the Foreign Trade (Development & Regulation) Act, 1992. The specific license affected is numbered 3111001781. Under Regulation 30(6), events not emanating from within the listed entity must be disclosed within twenty-four hours. Consequently, the disclosure was due by August 14, 2024, but was not made until October 1, 2026.

Additionally, the FDA, Maharashtra, administered a strict warning to the company under the Drugs and Cosmetics Act, 1940, via a letter dated January 10, 2025. This warning followed findings that Propylene Glycol manufactured by the company was declared "not of standard quality" by Government Analysts. The disclosure for this event was due by January 11, 2025, but remained unfiled until the recent submission.

Company Stance and Impact

Balaji Amines stated that there is no material impact on its financials, operations, or other activities resulting from these orders. The company initially withheld the DGFT disclosure because it believed the event did not fall within the ambit of events requiring immediate reporting under Schedule III of the SEBI (LODR) Regulations. Regarding the FDA warning, the company characterized it as a general communication of an advisory nature alleging no specific non-compliance. However, SEBI rejected this explanation, noting that the letter recorded specific show-cause notices and administered a strict warning in terms.

SEBI Directives and Future Compliance

SEBI viewed the non-compliances seriously and warned the company to improve its compliance standards. The regulator advised Balaji Amines to:

• Disclose the January 10, 2025, FDA letter and the August 13, 2024, DGFT order forthwith, along with explanations for the delay.
• Put in place adequate measures for timely disclosure of events specified in Schedule III.
• Place this warning letter and corrective steps taken before its Board of Directors.
• Disclose this letter to the stock exchanges immediately.

The company confirmed that it has now filed the necessary intimations to address the regulatory gaps identified by SEBI.

Balaji Amines Limited received a Directions and Warning Letter from the Food & Drug Administration, Pune, dated January 10, 2025. The regulatory action stems from the misuse of a technical grade chemical consignment by a third party, though the company faces no monetary penalty or prosecution.

The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company clarified that it sold a consignment of Propylene Glycol, designated for industrial use only, to a customer. Without Balaji Amines' knowledge or consent, the customer resold the material to a third party who utilized it for pharmaceutical purposes. This usage contravened provisions of the Drugs and Cosmetics Act, 1940.

Regulatory Action Details

The FDA issued a strict warning but did not impose any fine, initiate prosecution, or pass any adverse order against the listed entity. The company stated that there is no material impact on its financials, operations, or other activities resulting from this communication.

To prevent recurrence, Balaji Amines has reviewed its sales and documentation practices. Key corrective measures include:

• Clearly stating the intended end-use on invoices and labels.
• Obtaining end-use declarations from customers prior to sale.

Disclosure Timeline and Compliance

The company disclosed this event on October 1, 2026, following a directive from SEBI. In its explanation for the delay, Balaji Amines noted that it initially viewed the warning letter as falling outside the ambit of events requiring mandatory disclosure under Sub-para 20 of Para A of Part A of Schedule III of the SEBI LODR Regulations. The company submitted the disclosure after receiving a specific letter from SEBI dated September 29, 2026.

What the Numbers Show

The incident highlights a supply chain integrity risk rather than a direct operational failure by the manufacturer. While the company maintained that the product was sold strictly for industrial use, the downstream diversion to pharmaceutical applications triggered regulatory scrutiny. The absence of a financial penalty suggests the regulator accepted the company's lack of direct involvement in the misuse, focusing instead on future preventive controls.